In a report released on October 6, Thomas Smith from Leerink Partners reiterated a Buy rating on Abivax SA Sponsored ADR. The company’s shares closed yesterday at $87.01.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, MoonLake Immunotherapeutics, and Abivax SA Sponsored ADR. According to TipRanks, Smith has an average return of 43.9% and a 55.33% success rate on recommended stocks.
Currently, the analyst consensus on Abivax SA Sponsored ADR is a Strong Buy with an average price target of $109.71, implying a 26.09% upside from current levels. In a report released on October 6, LifeSci Capital also maintained a Buy rating on the stock with a $116.00 price target.
Based on Abivax SA Sponsored ADR’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.02 million and a GAAP net loss of $100.78 million. In comparison, last year the company earned a revenue of $3.39 million and had a GAAP net loss of $40.82 million
Read More on ABVX:
Disclaimer & DisclosureReport an Issue
- Abivax price target raised to $120 from $112 at BTIG
- Abivax’s Obefazimod: Promising Clinical Results and Market Potential Drive Buy Rating
- Abivax announces ABTECT 1, ABTECT 2 trials met primary endpoint
- Promising Phase 2b Results and Competitive Positioning Support Buy Rating for Abivax’s Obefazimod
- Abivax price target raised to $114 from $95 at Citizens JMP
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)
